{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:47:41Z","timestamp":1793710061532,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972741"],"award-info":[{"award-number":["81972741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273409"],"award-info":[{"award-number":["82273409"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515010300"],"award-info":[{"award-number":["2023A1515010300"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["2020B1212060018"],"award-info":[{"award-number":["2020B1212060018"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00280-023-04616-6","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:01:45Z","timestamp":1701432105000},"page":"237-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer"],"prefix":"10.1007","volume":"93","author":[{"given":"Xingyi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-5216","authenticated-orcid":false,"given":"Yinting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"4616_CR1","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20200401","author":"J Du","year":"2020","unstructured":"Du J, Gu J, Li J (2020) Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Biosci Rep. https:\/\/doi.org\/10.1042\/bsr20200401"},{"key":"4616_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","volume":"55","author":"T Okusaka","year":"2020","unstructured":"Okusaka T, Furuse J (2020) Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol 55:369\u2013382. https:\/\/doi.org\/10.1007\/s00535-020-01666-y","journal-title":"J Gastroenterol"},{"key":"4616_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na\u2019ara S, Gil Z (2015) Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat 23:55\u201368. https:\/\/doi.org\/10.1016\/j.drup.2015.10.002","journal-title":"Drug Resist Updat"},{"key":"4616_CR4","first-page":"1937","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Li Y, Xing C et al (2020) Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res 10:1937\u20131953","journal-title":"Am J Cancer Res"},{"key":"4616_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s1470-2045(10)70244-8","volume":"12","author":"LP Jordheim","year":"2011","unstructured":"Jordheim LP, S\u00e8ve P, Tr\u00e9dan O et al (2011) The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12:693\u2013702. https:\/\/doi.org\/10.1016\/s1470-2045(10)70244-8","journal-title":"Lancet Oncol"},{"key":"4616_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252917","volume":"16","author":"T Kato","year":"2021","unstructured":"Kato T, Ono H, Fujii M et al (2021) Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. PLoS ONE 16:e0252917. https:\/\/doi.org\/10.1371\/journal.pone.0252917","journal-title":"PLoS ONE"},{"key":"4616_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/cam4.2764","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhang L, Zheng H et al (2020) Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines. Cancer Med 9:1115\u20131130. https:\/\/doi.org\/10.1002\/cam4.2764","journal-title":"Cancer Med"},{"key":"4616_CR8","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1002\/cam4.2581","volume":"8","author":"F Mesmar","year":"2019","unstructured":"Mesmar F, Dai B, Ibrahim A et al (2019) Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med 8:7705\u20137719. https:\/\/doi.org\/10.1002\/cam4.2581","journal-title":"Cancer Med"},{"key":"4616_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/bib\/bbs046","volume":"14","author":"MA Dillies","year":"2013","unstructured":"Dillies MA, Rau A, Aubert J et al (2013) A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. Brief Bioinform 14:671\u2013683. https:\/\/doi.org\/10.1093\/bib\/bbs046","journal-title":"Brief Bioinform"},{"key":"4616_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D et al (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"key":"4616_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/genes12091339","author":"A Li","year":"2021","unstructured":"Li A, He J, Zhang Z et al (2021) Integrated bioinformatics analysis reveals marker genes and potential therapeutic targets for pulmonary arterial hypertension. Genes (Basel). https:\/\/doi.org\/10.3390\/genes12091339","journal-title":"Genes (Basel)"},{"key":"4616_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.809085","volume":"8","author":"R Bai","year":"2021","unstructured":"Bai R, Li Z, Hou Y et al (2021) Identification of diagnostic markers correlated with HIV(+) immune non-response based on bioinformatics analysis. Front Mol Biosci 8:809085. https:\/\/doi.org\/10.3389\/fmolb.2021.809085","journal-title":"Front Mol Biosci"},{"key":"4616_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118","journal-title":"OMICS"},{"key":"4616_CR14","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D et al (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47:D607-d613. https:\/\/doi.org\/10.1093\/nar\/gky1131","journal-title":"Nucleic Acids Res"},{"key":"4616_CR15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498\u20132504. https:\/\/doi.org\/10.1101\/gr.1239303","journal-title":"Genome Res"},{"issue":"Suppl 4","key":"4616_CR16","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-s4-s11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin CH, Chen SH, Wu HH et al (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8(Suppl 4):S11. https:\/\/doi.org\/10.1186\/1752-0509-8-s4-s11","journal-title":"BMC Syst Biol"},{"key":"4616_CR17","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B et al (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98-w102. https:\/\/doi.org\/10.1093\/nar\/gkx247","journal-title":"Nucleic Acids Res"},{"key":"4616_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.12.005","volume":"51","author":"L Yin","year":"2020","unstructured":"Yin L, Li W, Xu A et al (2020) SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo\/TEAD1-Twist1 pathway. EBioMedicine 51:102596. https:\/\/doi.org\/10.1016\/j.ebiom.2019.12.005","journal-title":"EBioMedicine"},{"key":"4616_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114085","volume":"189","author":"Y Tan","year":"2021","unstructured":"Tan Y, Li X, Tian Z et al (2021) TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Biochem Pharmacol 189:114085. https:\/\/doi.org\/10.1016\/j.bcp.2020.114085","journal-title":"Biochem Pharmacol"},{"key":"4616_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-62703-287-2_11","volume":"980","author":"W Qiu","year":"2013","unstructured":"Qiu W, Su GH (2013) Development of orthotopic pancreatic tumor mouse models. Methods Mol Biol 980:215\u2013223. https:\/\/doi.org\/10.1007\/978-1-62703-287-2_11","journal-title":"Methods Mol Biol"},{"key":"4616_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3747\/co.27.5211","volume":"27","author":"S Shakeel","year":"2020","unstructured":"Shakeel S, Finley C, Akhtar-Danesh G et al (2020) Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study. Curr Oncol 27:e1\u2013e8. https:\/\/doi.org\/10.3747\/co.27.5211","journal-title":"Curr Oncol"},{"key":"4616_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/1078-0432.Ccr-07-2247","volume":"14","author":"MP Kim","year":"2008","unstructured":"Kim MP, Gallick GE (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14:1284\u20131285. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-2247","journal-title":"Clin Cancer Res"},{"key":"4616_CR23","first-page":"3841","volume":"11","author":"X Fu","year":"2021","unstructured":"Fu X, Deng X, Xiao W et al (2021) Downregulation of NEAT1 sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine through modulation of the miR-506-3p\/ZEB2\/EMT axis. Am J Cancer Res 11:3841\u20133856","journal-title":"Am J Cancer Res"},{"key":"4616_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197307","author":"M Huber","year":"2020","unstructured":"Huber M, Brehm CU, Gress TM et al (2020) The immune microenvironment in pancreatic cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21197307","journal-title":"Int J Mol Sci"},{"key":"4616_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188384","volume":"1874","author":"TJ Li","year":"2020","unstructured":"Li TJ, Wang WQ, Yu XJ et al (2020) Killing the \u201cBAD\u201d: challenges for immunotherapy in pancreatic cancer. Biochim Biophys Acta Rev Cancer 1874:188384. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188384","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4616_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","volume":"86","author":"R Bhatia","year":"2022","unstructured":"Bhatia R, Bhyravbhatla N, Kisling A et al (2022) Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Semin Cancer Biol 86:499\u2013510. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.021","journal-title":"Semin Cancer Biol"},{"key":"4616_CR27","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1158\/1078-0432.Ccr-04-2159","volume":"11","author":"PO Berberat","year":"2005","unstructured":"Berberat PO, Dambrauskas Z, Gulbinas A et al (2005) Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11:3790\u20133798. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2159","journal-title":"Clin Cancer Res"},{"key":"4616_CR28","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.Can-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Carpenter ES, Steele NG et al (2021) Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-mediated production of CXCL1. Cancer Res 81:4305\u20134318. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-3929","journal-title":"Cancer Res"},{"key":"4616_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1101\/gad.284851.116","volume":"30","author":"EH Bent","year":"2016","unstructured":"Bent EH, Gilbert LA, Hemann MT (2016) A senescence secretory switch mediated by PI3K\/AKT\/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev 30:1811\u20131821. https:\/\/doi.org\/10.1101\/gad.284851.116","journal-title":"Genes Dev"},{"key":"4616_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.redox.2017.11.012","volume":"14","author":"QB Lu","year":"2018","unstructured":"Lu QB, Wan MY, Wang PY et al (2018) Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS\/NF\u03baB\/mTOR\/P70S6K signaling cascade. Redox Biol 14:656\u2013668. https:\/\/doi.org\/10.1016\/j.redox.2017.11.012","journal-title":"Redox Biol"},{"key":"4616_CR31","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1038\/onc.2009.158","volume":"28","author":"H Akita","year":"2009","unstructured":"Akita H, Zheng Z, Takeda Y et al (2009) Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28:2903\u20132909. https:\/\/doi.org\/10.1038\/onc.2009.158","journal-title":"Oncogene"},{"key":"4616_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/cncr.27619","volume":"119","author":"SB Fisher","year":"2013","unstructured":"Fisher SB, Patel SH, Bagci P et al (2013) An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer 119:445\u2013453. https:\/\/doi.org\/10.1002\/cncr.27619","journal-title":"Cancer"},{"key":"4616_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41416-018-0005-1","volume":"118","author":"NO Elander","year":"2018","unstructured":"Elander NO, Aughton K, Ghaneh P et al (2018) Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. Br J Cancer 118:1084\u20131088. https:\/\/doi.org\/10.1038\/s41416-018-0005-1","journal-title":"Br J Cancer"},{"key":"4616_CR34","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3389\/fonc.2019.00996","volume":"9","author":"M Wu","year":"2019","unstructured":"Wu M, Li X, Zhang T et al (2019) Identification of a nine-gene signature and establishment of a prognostic nomogram predicting overall survival of pancreatic cancer. Front Oncol 9:996. https:\/\/doi.org\/10.3389\/fonc.2019.00996","journal-title":"Front Oncol"},{"key":"4616_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/cad.0000000000000165","volume":"26","author":"H Yoneyama","year":"2015","unstructured":"Yoneyama H, Takizawa-Hashimoto A, Takeuchi O et al (2015) Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anticancer Drugs 26:90\u2013100. https:\/\/doi.org\/10.1097\/cad.0000000000000165","journal-title":"Anticancer Drugs"},{"key":"4616_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","volume":"96","author":"Y Nakano","year":"2007","unstructured":"Nakano Y, Tanno S, Koizumi K et al (2007) Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96:457\u2013463. https:\/\/doi.org\/10.1038\/sj.bjc.6603559","journal-title":"Br J Cancer"},{"key":"4616_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29:212\u2013226. https:\/\/doi.org\/10.1016\/j.tcb.2018.12.001","journal-title":"Trends Cell Biol"},{"key":"4616_CR38","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/sj.onc.1206232","volume":"22","author":"A Gautam","year":"2003","unstructured":"Gautam A, Li ZR, Bepler G (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22:2135\u20132142. https:\/\/doi.org\/10.1038\/sj.onc.1206232","journal-title":"Oncogene"},{"key":"4616_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070191","volume":"8","author":"Q Wang","year":"2013","unstructured":"Wang Q, Liu X, Zhou J et al (2013) Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PLoS ONE 8:e70191. https:\/\/doi.org\/10.1371\/journal.pone.0070191","journal-title":"PLoS ONE"},{"key":"4616_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682217","volume":"11","author":"W Du","year":"2021","unstructured":"Du W, Pasca di Magliano M, Zhang Y (2021) Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer. Front Oncol 11:682217. https:\/\/doi.org\/10.3389\/fonc.2021.682217","journal-title":"Front Oncol"},{"key":"4616_CR41","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3892\/ijo.2016.3616","volume":"49","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhang W, Yuan X et al (2016) Neutrophils in cancer development and progression: roles, mechanisms, and implications (review). Int J Oncol 49:857\u2013867. https:\/\/doi.org\/10.3892\/ijo.2016.3616","journal-title":"Int J Oncol"},{"key":"4616_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00281-022-00970-4","volume":"44","author":"S Notarbartolo","year":"2022","unstructured":"Notarbartolo S, Abrignani S (2022) Human T lymphocytes at tumor sites. Semin Immunopathol 44:883\u2013901. https:\/\/doi.org\/10.1007\/s00281-022-00970-4","journal-title":"Semin Immunopathol"},{"key":"4616_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","volume":"20","author":"GV Sharonov","year":"2020","unstructured":"Sharonov GV, Serebrovskaya EO, Yuzhakova DV et al (2020) B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol 20:294\u2013307. https:\/\/doi.org\/10.1038\/s41577-019-0257-x","journal-title":"Nat Rev Immunol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04616-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T21:08:13Z","timestamp":1709154493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["4616"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04616-6","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}